Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.42 -0.3%	$7.55	$5.90 ▼ $29.61	$543.06M	2.22	1.84 million shs	1.47 million shs
ATYR aTyr Pharma	$4.70 -0.4%	$5.23	$1.67 ▼ $7.29	$420.10M	0.94	5.74 million shs	4.25 million shs
NKTX Nkarta	$2.12 -2.3%	$1.87	$1.31 ▼ $6.63	$153.98M	0.72	567,093 shs	472,909 shs
RAPP Rapport Therapeutics	$14.15 -1.5%	$12.70	$6.43 ▼ $29.74	$524.11M	0.6	161,022 shs	124,280 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-0.27%	-5.36%	-6.08%	-3.89%	-73.03%
ATYR aTyr Pharma	-0.42%	-19.38%	-10.98%	+30.56%	+137.37%
NKTX Nkarta	-2.30%	-1.85%	+21.84%	+1.44%	-67.03%
RAPP Rapport Therapeutics	-1.46%	-11.84%	+19.92%	+24.89%	-37.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.4676 of 5 stars	4.3	2.0	2.3	2.5	1.3
ATYR aTyr Pharma	2.5542 of 5 stars	3.6	1.0	3.8	1.7	0.6
NKTX Nkarta	2.416 of 5 stars	3.6	0.0	4.3	1.7	0.6
RAPP Rapport Therapeutics	1.1907 of 5 stars	3.5	0.0	0.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$20.29	173.44% Upside
ATYR aTyr Pharma	3.14	Buy	$20.20	329.79% Upside
NKTX Nkarta	3.13	Buy	$14.33	576.10% Upside
RAPP Rapport Therapeutics	3.00	Buy	$28.00	97.88% Upside

Current Analyst Ratings Breakdown

Latest NKTX, ARVN, RAPP, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/15/2025	ARVN Arvinas	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $21.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	2.06	N/A	N/A	$8.17 per share	0.91
ATYR aTyr Pharma	$230K	1,818.70	N/A	N/A	$0.83 per share	5.66
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$8.35 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-10.92%	-7.74%	-4.11%	8/6/2025 (Estimated)
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
RAPP Rapport Therapeutics	-$78.31M	-$3.45	N/A	N/A	N/A	N/A	-25.48%	-24.63%	8/14/2025 (Estimated)

Latest NKTX, ARVN, RAPP, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RAPP Rapport Therapeutics	-$0.87	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	N/A	N/A	N/A	$34.42 million	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/8/2025	Q1 2025	RAPP Rapport Therapeutics	-$0.77	-$0.68	+$0.09	-$0.68	N/A	N/A
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	4.58	4.58
ATYR aTyr Pharma	0.01	7.79	7.79
NKTX Nkarta	N/A	14.48	14.48
RAPP Rapport Therapeutics	N/A	31.01	31.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
ATYR aTyr Pharma	61.72%
NKTX Nkarta	80.54%
RAPP Rapport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
ATYR aTyr Pharma	3.70%
NKTX Nkarta	8.40%
RAPP Rapport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	72.99 million	69.54 million	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A

NKTX, ARVN, RAPP, and ATYR Headlines

Recent News About These Companies

Rapport Therapeutics Inc. (RAPP) Stock Price Today - WSJ

July 26, 2025 | wsj.com

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 9.1% - Here's Why

July 25, 2025 | marketbeat.com

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Insider Sells $119,000.00 in Stock

July 16, 2025 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.3% - Time to Buy?

July 16, 2025 | marketbeat.com

AI therapy bots fuel delusions and give dangerous advice, Stanford study finds

July 11, 2025 | arstechnica.comA

Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.3% - Should You Sell?

July 11, 2025 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Trading 9.8% Higher - Here's Why

July 9, 2025 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Receives "Market Outperform" Rating from JMP Securities

July 8, 2025 | marketbeat.com

Rapport Therapeutics stock rating reiterated as Buy by TD Cowen

July 2, 2025 | uk.investing.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)

...

June 12, 2025 | marketbeat.com

Stifel reiterates buy rating for Rapport Therapeutics stock

June 5, 2025 | uk.investing.com

Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline

June 4, 2025 | nasdaq.com

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

June 2, 2025 | globenewswire.com

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025 | globenewswire.com

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 21, 2025 | globenewswire.com

Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth

May 16, 2025 | finance.yahoo.com

Rapport Therapeutics Reports Q1 2025 Financial Results

May 9, 2025 | tipranks.com

Optimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 Developments

May 8, 2025 | tipranks.com

Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.

May 8, 2025 | tipranks.com

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

May 8, 2025 | globenewswire.com

Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform

May 7, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?
By Leo Miller | July 31, 2025
View Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?

NKTX, ARVN, RAPP, and ATYR Company Descriptions

Arvinas NASDAQ:ARVN

$7.42 -0.02 (-0.27%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$7.42 +0.00 (+0.07%)

As of 08/1/2025 06:07 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

aTyr Pharma NASDAQ:ATYR

$4.70 -0.02 (-0.42%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.73 +0.03 (+0.72%)

As of 08/1/2025 07:55 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Nkarta NASDAQ:NKTX

$2.12 -0.05 (-2.30%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.04 (-2.12%)

As of 08/1/2025 07:45 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Rapport Therapeutics NASDAQ:RAPP

$14.15 -0.21 (-1.46%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$14.16 +0.01 (+0.07%)

As of 08/1/2025 07:56 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time